PALI PALISADE BIO, INC.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1357459 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-289.2%
TTM EPS YoY144.4%
Revenue 3-yr CAGR-98.7%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-9,625,400,000.0%
Net margin-8,739,200,000.0%
FCF margin—
EBITDA margin-9,625,400,000.0%
Returns
ROE-75.6%
ROA-69.6%
ROIC (approx.)—
Asset turnover0.00x
Leverage & solvency
Liabilities / assets5.1%
Debt / equity0.00x
Current ratio20.16x
Interest coverage-16,042.33x
Cash quality & payout
Operating cash flow / net income0.60x
Accruals ratio-27.6%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $0 | $0 | $250,000 | $0 | — |
| R&D expense | $10.19M | $16.00M | $6.89M | $6.55M | $2.43M |
| SG&A expense | $7.86M | $5.80M | $6.20M | $8.76M | $9.31M |
| Operating income | -$18.06M | -$14.86M | -$13.07M | -$15.72M | -$41.85M |
| Interest expense | $10,000 | $12,000 | $15,000 | $13,000 | $2.40M |
| Income tax | $0 | $0 | $0 | $0 | $0 |
| Net income | -$16.78M | -$14.44M | -$12.30M | -$14.26M | -$26.62M |
| EBITDA | -$18.05M | -$14.86M | -$13.07M | -$15.72M | -$41.85M |
| EPS (basic) | -0.30 | -10.19 | -27.01 | -16.53 | -142.95 |
| EPS (diluted) | -0.30 | -10.19 | -27.01 | -16.53 | -169.74 |
| Weighted avg. shares (diluted) | 55.67M | 1.42M | 456,014 | 880,311 | 186,958 |
| Balance sheet | |||||
| Cash & equivalents | $133.38M | $9.82M | $12.43M | $12.38M | $10.49M |
| Receivables | $0 | $0 | — | $0 | $0 |
| Current assets | $134.22M | $10.49M | $13.33M | $14.73M | $11.51M |
| PP&E, net | $0 | $3,000 | $10,000 | $10,000 | $3,000 |
| Total assets | $134.34M | $10.88M | $14.05M | $15.76M | $12.51M |
| Current liabilities | $4.64M | $3.24M | $2.59M | $3.01M | $2.50M |
| Short-term debt | — | — | — | — | $87,000 |
| Long-term debt | — | — | — | — | $0 |
| Total debt | — | — | — | — | $87,000 |
| Total liabilities | $4.96M | $3.39M | $2.74M | $3.28M | $5.15M |
| Shareholders' equity | $129.38M | $7.49M | $11.31M | $12.48M | $7.37M |
| Net debt | — | — | — | — | -$10.41M |
| Shares outstanding | 159.44M | 2.77M | 618,056 | 2.94M | 284,780 |
| Cash flow statement | |||||
| Operating cash flow | -$10.85M | -$12.19M | -$11.13M | -$13.36M | -$14.77M |
| Capital expenditure | — | $0 | $4,000 | $10,000 | $0 |
| Free cash flow | — | -$12.19M | -$11.14M | -$13.37M | -$14.77M |
| Investing cash flow | — | $0 | -$4,000 | -$10,000 | -$54,000 |
| Financing cash flow | $134.44M | $9.58M | $11.19M | $15.26M | $24.61M |
| Depreciation & amortization | $3,000 | $3,000 | $4,000 | $3,000 | $2,000 |
| Stock-based compensation | $3.96M | $652,000 | $624,000 | $1.03M | $1.89M |
Free plan shows the latest 5 periods; Pro shows all 17 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.